Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.

<h4>Objective</h4>Lipid lowering therapy is widely used for the prevention of cardiovascular complications after acute myocardial infarction (AMI). However, some studies show that this benefit is uncertain in patients with renal dysfunction, and the role of statins is based on the severi...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin Sug Kim, Weon Kim, Ji Yoon Park, Jong Shin Woo, Tae Won Lee, Chun Gyoo Ihm, Yang Gyun Kim, Ju-Young Moon, Sang Ho Lee, Myung Ho Jeong, Kyung Hwan Jeong, Korea Acute Myocardial Infarction Registry Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183059&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849715562856316928
author Jin Sug Kim
Weon Kim
Ji Yoon Park
Jong Shin Woo
Tae Won Lee
Chun Gyoo Ihm
Yang Gyun Kim
Ju-Young Moon
Sang Ho Lee
Myung Ho Jeong
Kyung Hwan Jeong
Korea Acute Myocardial Infarction Registry Investigators
author_facet Jin Sug Kim
Weon Kim
Ji Yoon Park
Jong Shin Woo
Tae Won Lee
Chun Gyoo Ihm
Yang Gyun Kim
Ju-Young Moon
Sang Ho Lee
Myung Ho Jeong
Kyung Hwan Jeong
Korea Acute Myocardial Infarction Registry Investigators
author_sort Jin Sug Kim
collection DOAJ
description <h4>Objective</h4>Lipid lowering therapy is widely used for the prevention of cardiovascular complications after acute myocardial infarction (AMI). However, some studies show that this benefit is uncertain in patients with renal dysfunction, and the role of statins is based on the severity of renal dysfunction. In this study, we investigated the impact of statin therapy on major adverse cardiac events (MACEs) and all-cause mortality in patients with advanced renal dysfunction undergoing percutaneous coronary intervention (PCI) after AMI.<h4>Methods</h4>This study was based on the Korea Acute Myocardial Infarction Registry database. We included 861 patients with advanced renal dysfunction from among 33,205 patients who underwent PCI after AMI between November 2005 and July 2012. Patients were divided into two groups: a statin group (n = 537) and a no-statin group (n = 324). We investigated the 12-month MACEs (cardiac death, myocardial infarction, repeated PCI or coronary artery bypass grafting) and all-cause mortality of each group. Subsequently, a propensity score-matched analysis was performed.<h4>Results</h4>In the total population studied, no significant differences were observed between the two groups with respect to the rate of recurrent MI, repeated PCI, coronary artery bypass grafting (CABG), or all-cause mortality. However, the cardiac death rate was significantly lower in the statin group (p = 0.009). Propensity score-matched analysis yielded 274 pairs demonstrating, results similar to those obtained from the total population. However, there was no significant difference in the cardiac death rate in the propensity score-matched population (p = 0.103). Cox-regression analysis revealed only left ventricular ejection fraction to be an independent predictor of 12-month MACEs (Hazard ratio [HR] of 0.979, 95% confidence interval [CI], 0962-0.996, p = 0.018).<h4>Conclusions</h4>Statin therapy was not significantly associated with a reduction in the 12-month MACEs or all-cause mortality in patients with advanced renal dysfunction undergoing PCI after AMI.
format Article
id doaj-art-427a7e4b681f49d4bafcf8b83b786499
institution DOAJ
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-427a7e4b681f49d4bafcf8b83b7864992025-08-20T03:13:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01128e018305910.1371/journal.pone.0183059Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.Jin Sug KimWeon KimJi Yoon ParkJong Shin WooTae Won LeeChun Gyoo IhmYang Gyun KimJu-Young MoonSang Ho LeeMyung Ho JeongKyung Hwan JeongKorea Acute Myocardial Infarction Registry Investigators<h4>Objective</h4>Lipid lowering therapy is widely used for the prevention of cardiovascular complications after acute myocardial infarction (AMI). However, some studies show that this benefit is uncertain in patients with renal dysfunction, and the role of statins is based on the severity of renal dysfunction. In this study, we investigated the impact of statin therapy on major adverse cardiac events (MACEs) and all-cause mortality in patients with advanced renal dysfunction undergoing percutaneous coronary intervention (PCI) after AMI.<h4>Methods</h4>This study was based on the Korea Acute Myocardial Infarction Registry database. We included 861 patients with advanced renal dysfunction from among 33,205 patients who underwent PCI after AMI between November 2005 and July 2012. Patients were divided into two groups: a statin group (n = 537) and a no-statin group (n = 324). We investigated the 12-month MACEs (cardiac death, myocardial infarction, repeated PCI or coronary artery bypass grafting) and all-cause mortality of each group. Subsequently, a propensity score-matched analysis was performed.<h4>Results</h4>In the total population studied, no significant differences were observed between the two groups with respect to the rate of recurrent MI, repeated PCI, coronary artery bypass grafting (CABG), or all-cause mortality. However, the cardiac death rate was significantly lower in the statin group (p = 0.009). Propensity score-matched analysis yielded 274 pairs demonstrating, results similar to those obtained from the total population. However, there was no significant difference in the cardiac death rate in the propensity score-matched population (p = 0.103). Cox-regression analysis revealed only left ventricular ejection fraction to be an independent predictor of 12-month MACEs (Hazard ratio [HR] of 0.979, 95% confidence interval [CI], 0962-0.996, p = 0.018).<h4>Conclusions</h4>Statin therapy was not significantly associated with a reduction in the 12-month MACEs or all-cause mortality in patients with advanced renal dysfunction undergoing PCI after AMI.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183059&type=printable
spellingShingle Jin Sug Kim
Weon Kim
Ji Yoon Park
Jong Shin Woo
Tae Won Lee
Chun Gyoo Ihm
Yang Gyun Kim
Ju-Young Moon
Sang Ho Lee
Myung Ho Jeong
Kyung Hwan Jeong
Korea Acute Myocardial Infarction Registry Investigators
Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
PLoS ONE
title Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
title_full Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
title_fullStr Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
title_full_unstemmed Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
title_short Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis.
title_sort effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction a propensity score matched analysis
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183059&type=printable
work_keys_str_mv AT jinsugkim effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT weonkim effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT jiyoonpark effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT jongshinwoo effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT taewonlee effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT chungyooihm effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT yanggyunkim effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT juyoungmoon effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT sangholee effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT myunghojeong effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT kyunghwanjeong effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis
AT koreaacutemyocardialinfarctionregistryinvestigators effectsofstatintherapyonclinicaloutcomesafteracutemyocardialinfarctioninpatientswithadvancedrenaldysfunctionapropensityscorematchedanalysis